A phase 2 Randomized Controlled Trial of Adjuvant Tumor-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-selected High-Risk Nasopharyngeal Carcinoma Patients

420 locoregionally advanced NPC patients underwent pEBV DNA screening. 156 patients (37.1%) who had pEBV DNA =4000 copies/mL were included and randomly assigned to CCRT plus TIL infusion group (n=78) and CCRT alone group (n=78). Outcomes were classified as patients with a poor outcome (nonresponders) and patients with a favorable outcome (responders). Single cell RNA sequencing (scRNA-seq) for infused TIL products in responder and non-responder. Overall design: We profiled 4 TIL infusion products from patient with Epstein-Barr Virus DNA-selected High-Risk Nasopharyngeal Carcinoma treated with CCRT and TIL (responder, n=2; nonresponder, n=2), using single-cell transcriptomics.